Dr Pavan Bhargava gives insights on earlier diagnosis, ocrelizumab safety in pregnancy, and promising anti-aging effects of diet in RRMS.

Tolebrutinib, a brain-penetrant BTK inhibitor, may fill a significant unmet need by delaying disability progression in patients with non-relapsing secondary progressive multiple sclerosis.

A University of Alberta study shows that rural Albertans living with multiple sclerosis are not as likely as urban patients to receive the best treatments to prevent relapses and slow down progression ...

Two researchers win the Breakthrough Prize in Life Sciences for their discoveries related to multiple sclerosis disease ...

Under the collaboration, Biostate AI will sequence patient samples from the ACP Repository, one of the world's largest and most comprehensive MS-related collections of biospecimens and clinical data.

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...

That's because Greg, an engineer, rode his bike in the MS 150, a punishing ride, formerly between Houston and Austin. (The ...

Depression and anxiety have been well documented in people with multiple sclerosis (MS), but often are undiagnosed or ...

Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...

OSU scientists created nanoparticles that deliver anti-inflammatory drugs across the blood-brain barrier, offering hope for ...

Dr. Stephen Hauser, a Ross resident who is a neurology professor at UCSF, “overturned the scientific consensus” about the ...